| 1.49 -0.23 (-13.37%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.19  |
1-year : | 4.12 |
| Resists | First : | 2.73 |
Second : | 3.52 |
| Pivot price | 2.54 |
|||
| Supports | First : | 1.46 |
Second : | 1.21 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 2.71 |
| MA(100) : | 3.87 |
MA(250) : | 7.13 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 20.8 |
D(3) : | 37.2 |
| RSI | RSI(14): 26.7 |
|||
| 52-week | High : | 62.95 | Low : | 1.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PBM ] has closed below the lower bollinger band by 14.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PBM ] is to continue within current trading range. It is unclear right now based on current values. 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.73 | 1.73 - 1.74 |
| Low: | 1.44 - 1.45 | 1.45 - 1.46 |
| Close: | 1.47 - 1.49 | 1.49 - 1.5 |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Thu, 20 Nov 2025
Is PBM’s Market Boost a Fleeting Mirage? - StocksToTrade
Thu, 20 Nov 2025
Is It Time to Buy PBM Stock? - timothysykes.com
Thu, 20 Nov 2025
Psyence BioMed Reaches Major Breakthrough in - GlobeNewswire
Thu, 20 Nov 2025
Psyence BioMed (Nasdaq: PBM) secures 50kg ibogaine supply for global clinical use - Stock Titan
Thu, 06 Nov 2025
Psyence BioMed (Nasdaq: PBM) doses in Phase IIb; 87-patient trial targets topline 2026 - Stock Titan
Mon, 03 Nov 2025
Psyence BioMed (Nasdaq: PBM) invests $3,500,000 in PsyLabs for GMP-grade API supply - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 79 (K) |
| Shares Short P.Month | 66 (K) |
| EPS | 41.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|